The preclinical study of 177 Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer.

Sajjad MolavipordanjaniTahoora MousaviAlireza KhorramimoghaddamFereshteh Talebpour AmiriSeyed Mohammad AbediSeyed Jalal Hosseinimehr

Published in: Annals of nuclear medicine (2023)

Lu-DOTA-LTVSPWY can recognize HER2 receptors in vivo and in vitro; hence, it can serve as a therapeutic agent.

Keyphrases